Have a personal or library account? Click to login
Epigenetics and cancer – A dependence relationship Cover

Epigenetics and cancer – A dependence relationship

Forum of Clinical Oncology
Volume 12 (2021): Issue 3 (December 2021)
By:
Open Access
|Oct 2022

References

  1. Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 2022 Mar;289(5):1214–1239. doi: <a href="https://doi.org/10.1111/febs.15750." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/febs.15750.</a> Epub 2021 Feb 18. PMID: 33545740.
    Open DOISearch in Google ScholarBack to article
  2. Liu Z, Ren Y, Weng S, Xu H, Li L, Han X. A New trend in cancer treatment: the combination of epigenetics and immunotherapy. Front Immunol. 2022 Jan 24;13:809761. doi: <a href="https://doi.org/10.3389/fimmu.2022.809761." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fimmu.2022.809761.</a> PMID: 35140720; PMCID: PMC8818678.
    Open DOISearch in Google ScholarBack to article
  3. Schübeler D. Function and information content of DNA methylation. Nature. 2015 Jan 15;517(7534):321–6. doi: <a href="https://doi.org/10.1038/nature14192." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/nature14192.</a> PMID: 25592537.
    Open DOISearch in Google ScholarBack to article
  4. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000 Dec 15;165(12):7017–24. doi: <a href="https://doi.org/10.4049/jimmunol.165.12.7017." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.4049/jimmunol.165.12.7017.</a> PMID: 11120829.
    Open DOISearch in Google ScholarBack to article
  5. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015 Aug 27;162(5):961–73. doi: <a href="https://doi.org/10.1016/j.cell.2015.07.056." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.cell.2015.07.056.</a> PMID: 26317465; PMCID: PMC4843502.
    Open DOISearch in Google ScholarBack to article
  6. Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget. 2017 Jun 27;8(26):42214–42225. doi: <a href="https://doi.org/10.18632/oncotarget.15031." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.15031.</a> PMID: 28178682; PMCID: PMC5522061.
    Open DOISearch in Google ScholarBack to article
  7. Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, et al. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget. 2016 Nov 29;7(48):79943–79955. doi: <a href="https://doi.org/10.18632/oncotarget.13161." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.18632/oncotarget.13161.</a> PMID: 27835597; PMCID: PMC5346762.
    Open DOISearch in Google ScholarBack to article
  8. Karamitrousis EI, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients. Technol Cancer Res Treat. 2021 Jan–Dec;20:1533033820973279. doi: <a href="https://doi.org/10.1177/1533033820973279." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1177/1533033820973279.</a> PMID: 33928818; PMCID: PMC8113658.
    Open DOISearch in Google ScholarBack to article
  9. Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer. Clin Chem Lab Med. 2020 Sep 1;59(2):e73–e75. doi: <a href="https://doi.org/10.1515/cclm-2020-0662." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1515/cclm-2020-0662.</a> PMID: 32870805.
    Open DOISearch in Google ScholarBack to article
  10. Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, et al. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunol Res. 2015 Sep;3(9):1030–41. doi: <a href="https://doi.org/10.1158/2326-6066.CIR-15-0073." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/2326-6066.CIR-15-0073.</a> Epub 2015 Jun 8. PMID: 26056145.
    Open DOISearch in Google ScholarBack to article
  11. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015 Aug 27;162(5):974–86. doi: <a href="https://doi.org/10.1016/j.cell.2015.07.011." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.cell.2015.07.011.</a> Erratum in: Cell. 2016 Feb 25;164(5):1073. Buhu, Sadna [corrected to Budhu, Sadna]; Mergoub, Taha [corrected to Merghoub, Taha]. Erratum in: Cell. 2017 Apr 6;169(2):361. PMID: 26317466; PMCID: PMC4556003.
    Open DOISearch in Google ScholarBack to article
  12. Leslie M. First EZH2 Inhibitor Approved-for Rare Sarcoma. Cancer Discov. 2020 Mar;10(3):333–334. doi: <a href="https://doi.org/10.1158/2159-8290.CD-NB2020-006." target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1158/2159-8290.CD-NB2020-006.</a> Epub 2020 Feb 10. PMID: 32041739.
    Open DOISearch in Google ScholarBack to article
  13. Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Concentration of circulating tumor DNA in patients with metastatic gastric cancer and its prognostic significance. Forum Clin Oncol. 2021; 12(2): 72–76.
    Search in Google ScholarBack to article
  14. Goni M, Javaregowda PK, Chachadi V, Virupakshaiah DBM. Sialic acids: An avenue to target cancer progression, mestastasis and resistance to therapy. Forum Clin Oncol. 2021;12(2):
    Search in Google ScholarBack to article
  15. Sharma H, Kumar G, Kaur CD. Development of bioflavonoid containing chemotherapeutic delivery systems for UV damaged skin and kangri cancer. Forum Clin Oncol. 2021;12 (2): 86–98.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/fco-2022-0025 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 1 - 2
Submitted on: Mar 29, 2022
Accepted on: Mar 31, 2022
Published on: Oct 23, 2022
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2022 Evangelos Karamitrousis, Michalis Liontos, Nikolaos Tsoukalas, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 12 (2021): Issue 3 (December 2021)Next article